In the vast landscape of pharmaceutical research and development, one significant challenge that researchers face is the availability of suitable compounds for their studies. Commercially available compounds often come with limitations, either due to their unavailability or patent protection. However, custom chemical synthesis has emerged as a game-changer, offering a solution that breaks free from these commercial limitations. By enabling the creation of unique compounds tailored to specific needs, custom synthesis opens up a world of possibilities for pharmaceutical companies, allowing them ..read more

The $1 billion acquisition deal is set to advance Ironwood’s vision of becoming the leading gastrointestinal healthcare company. Ironwood Pharmaceuticals, Inc., a company focused on gastrointestinal (GI) healthcare, and VectivBio Holding AG, a clinical-stage biopharmaceutical company specialising in transformative treatments for severe rare gastrointestinal conditions, have announced a definitive agreement for Ironwood to acquire VectivBio. The acquisition will be an all-cash transaction at $17.00 per share, totaling approximately $1 billion, taking into account VectivBio’s cash and debt. The ..read more

We’re delighted to share that ATMOsphere has acknowledged MIRAI Intex as an exceptional company in the field of natural refrigerants – a testament to MIRAI’s expertise in creating cutting-edge refrigeration systems. As a leading global player, MIRAI Intex’s team takes great pride in being at the forefront of promoting sustainability and environmental stewardship. High-performance, sustainable refrigeration solutions MIRAI Intex has a longstanding commitment to creating high-performance refrigeration solutions that prioritise environmental sustainability while catering to the unique requirement ..read more

Coya Therapeutics’ investigational low-dose interleukin-2 (IL-2) for subcutaneous administration, COYA 301, has been found to increase Treg function and halt the cognitive decline in an Open Label Study in patients with Alzheimer’s disease. Texas-based Coya Therapeutics, a clinical-stage biotechnology company focused on developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, has announced the findings from an open-label proof-of-concept clinical study for COYA 301 in Alzheimer’s Disease (AD) patients. COYA 301 is Coya’s investigation ..read more

The Weather Instrument Shelter is an accessory specifically designed to protect temperature and humidity measurements from the influence of unwanted weather conditions, such as rain or solar radiation. It is a versatile product that can be mounted easily on poles or other objects, making it suitable for use in various settings. The shelter is made of durable UV-resistant material and comes with a stainless-steel mounting bracket, which ensures a long service life. Weather Instrument Shelter Ensures Accurate and Reliable Data Investing in the Weather Instrument Shelter guarantees the accuracy a ..read more

For over 40 years, L.B. Bohle has been at the forefront of technological advancements in the pharmaceutical industry. Now the company is fusing its cutting-edge technology with contemporary aesthetics. Fusing Cutting-Edge Technology with Contemporary Aesthetics Thorsten Wesselmann, Executive Director Technology at L.B. Bohle Maschinen und Verfahren GmbH, explains: “Now the development team has decided to combine premium technology with modern design in the future.” The L.B. Bohle’s team has dedicated over two years to the engineering and creation of these new machines, with the support of e ..read more

Eisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate (ADC), with the option to pursue a strategic collaboration. BB-1701 is an antibody-drug conjugate (ADC) that combines Eisai’s eribulin anticancer agent with an anti-HER2 antibody via a linker. The drug is anticipated to have a positive impact on breast, lung, and other solid tumors that express HER2. Eisai’s proprietary technology platform, which employs eribulin as a payload, is responsible for the linker-payload mechanism, and Eisai is currently rese ..read more

Astellas Pharma Inc announced that the US Food and Drug Administration (FDA) has given approval for the oral drug VEOZAHTM (fezolinetant) 45 mg to treat moderate to severe vasomotor symptoms (VMS) caused by menopause. This is the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved for this purpose. VMS symptoms can include hot flashes and night sweats. These common symptoms of menopause can significantly impact women’s daily activities and overall quality of life. Genevieve Neal-Perry, M.D., Ph.D., Chair, UNC School of Medicine Department of Obstetrics and Gynecology said: “Toda ..read more

The SenseAnywhere AccessPoint is a reliable, plug-and-play device designed to connect SenseAnywhere’s wireless Sensors to the SenseAnywhere Cloud service. The wireless communication between the sensors and network is fully encrypted, with two-way communication, ensuring the secure transmission of all data. Water and dustproof, the AccessPoint is ideal for outdoor use. Reliability and Security Features of the Outdoor AccessPoint The SenseAnywhere AccessPoint is designed to provide reliable and secure wireless communication, making it ideal for the pharmaceutical industry. The sensors automatica ..read more

The leading manufacturer of eco-friendly ultra-low temperature refrigeration systems, MIRAI INTEX, and pharmaceutical transportation experts, Gebr. Thomaidis, are thrilled to announce a new joint project to all professionals in the transportation and pharmaceutical industries: the Thomaidis ULT Truck with integrated MIRAI Cold Machine. As the demand for temperature-controlled transportation rises across various industries such as pharmaceuticals, food and beverage, and chemicals, the need for a dependable and environmentally friendly solution becomes crucial. This is where MIRAI INTEX steps in ..read more